Video
Dr. Spratt on “substantial benefit” of Decipher test for patients with intermediate-risk prostate cancer
Author(s):
“It's the first time that any gene expression test has been analyzed in a randomized trial, even if it's post-hoc, in intermediate-risk patients,” says Daniel E. Spratt, MD.
In this video, Daniel E. Spratt, MD, discusses the background and findings of the study, “Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126,” which was shared during the 2022 ASCO Genitourinary Cancers Symposium. Spratt is a Vincent K. Smith professor and chair at Case Western Reserve University School of Medicine and chair of radiation oncology at University Hospitals Cleveland Medical Center in Cleveland, Ohio.
Related Videos
Related Content
